I am a bit surprised that we are not at least over the $3 mark, similar price point as 2018 on expecting news with partnering of Trof.
Approaching the end of phase 3 trial for the actual partnered deal, looking at potential success, closing in on potential revenue, potential $$ ROW, news front on a number of fronts.
NZ-2591 is now well progressed adding value since 2018 now heading into funded phase 2 trials.
Analysts coverage $3.60 p/sh few months back now.
Still cheap $284m MC,
Ann: Trofinetide Rett syndrome clinical trial in girls aged 2-5, page-30
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |